Apomorphine in the treatment of Parkinson's disease: a review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos de neuro-psiquiatria (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018001200840 |
Resumo: | ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment. |
id |
ABNEURO-1_05ace27cfe6c588911705587bc8a0682 |
---|---|
oai_identifier_str |
oai:scielo:S0004-282X2018001200840 |
network_acronym_str |
ABNEURO-1 |
network_name_str |
Arquivos de neuro-psiquiatria (Online) |
repository_id_str |
|
spelling |
Apomorphine in the treatment of Parkinson's disease: a reviewApomorphinedopaminer agentsParkinsons diseasereviewABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment.Academia Brasileira de Neurologia - ABNEURO2018-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018001200840Arquivos de Neuro-Psiquiatria v.76 n.12 2018reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20180140info:eu-repo/semantics/openAccessPessoa,Renata RaminaMoro,AdrianaMunhoz,Renato PuppiTeive,Hélio A.G.Lees,Andrew J.eng2019-01-18T00:00:00Zoai:scielo:S0004-282X2018001200840Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2019-01-18T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse |
dc.title.none.fl_str_mv |
Apomorphine in the treatment of Parkinson's disease: a review |
title |
Apomorphine in the treatment of Parkinson's disease: a review |
spellingShingle |
Apomorphine in the treatment of Parkinson's disease: a review Pessoa,Renata Ramina Apomorphine dopaminer agents Parkinsons disease review |
title_short |
Apomorphine in the treatment of Parkinson's disease: a review |
title_full |
Apomorphine in the treatment of Parkinson's disease: a review |
title_fullStr |
Apomorphine in the treatment of Parkinson's disease: a review |
title_full_unstemmed |
Apomorphine in the treatment of Parkinson's disease: a review |
title_sort |
Apomorphine in the treatment of Parkinson's disease: a review |
author |
Pessoa,Renata Ramina |
author_facet |
Pessoa,Renata Ramina Moro,Adriana Munhoz,Renato Puppi Teive,Hélio A.G. Lees,Andrew J. |
author_role |
author |
author2 |
Moro,Adriana Munhoz,Renato Puppi Teive,Hélio A.G. Lees,Andrew J. |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Pessoa,Renata Ramina Moro,Adriana Munhoz,Renato Puppi Teive,Hélio A.G. Lees,Andrew J. |
dc.subject.por.fl_str_mv |
Apomorphine dopaminer agents Parkinsons disease review |
topic |
Apomorphine dopaminer agents Parkinsons disease review |
description |
ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and continuous process with direct impact on patients’ quality of life. The basic tenet of this task entails tailored therapy, allowing for optimal motor function with the fewest adverse effects. Apomorphine, a dopamine agonist used as rescue therapy for patients with motor fluctuations, with potential positive effects on nonmotor symptoms, is the only antiparkinsonian agent whose capacity to control motor symptoms is comparable to that of levodopa. Subcutaneous administration, either as an intermittent injection or as continuous infusion, appears to be the most effective and tolerable route. This review summarizes the historical background, structure, mechanism of action, indications, contraindications and side effects, compares apomorphine infusion therapy with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018001200840 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2018001200840 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/0004-282x20180140 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
publisher.none.fl_str_mv |
Academia Brasileira de Neurologia - ABNEURO |
dc.source.none.fl_str_mv |
Arquivos de Neuro-Psiquiatria v.76 n.12 2018 reponame:Arquivos de neuro-psiquiatria (Online) instname:Academia Brasileira de Neurologia instacron:ABNEURO |
instname_str |
Academia Brasileira de Neurologia |
instacron_str |
ABNEURO |
institution |
ABNEURO |
reponame_str |
Arquivos de neuro-psiquiatria (Online) |
collection |
Arquivos de neuro-psiquiatria (Online) |
repository.name.fl_str_mv |
Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia |
repository.mail.fl_str_mv |
||revista.arquivos@abneuro.org |
_version_ |
1754212784569057280 |